Combination of bromodomain inhibitor JQ1 with MEK inhibitor PD-901 showed strong activity on killing PRC2-loss-function and NF1 mutant malignant peripheral nerve sheath tumors (MPNSTs) [53], which provides rationality for that combination of GSK126 and bortezomib in our study may be a good way to prevent GSK126 resistance in MM treatment. The gene discussed is NF1; the disease is cancer.